GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ReNeuron Group PLC (OTCPK:RNUGF) » Definitions » ROE % Adjusted to Book Value

RNUGF (ReNeuron Group) ROE % Adjusted to Book Value : -87.00% (As of Sep. 2023)


View and export this data going back to 2006. Start your Free Trial

What is ReNeuron Group ROE % Adjusted to Book Value?

ReNeuron Group's ROE % for the quarter that ended in Sep. 2023 was -153.99%. ReNeuron Group's PB Ratio for the quarter that ended in Sep. 2023 was 1.77. ReNeuron Group's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2023 was -87.00%.


ReNeuron Group ROE % Adjusted to Book Value Historical Data

The historical data trend for ReNeuron Group's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ReNeuron Group ROE % Adjusted to Book Value Chart

ReNeuron Group Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -32.83 -22.51 -20.03 -38.72 -84.56

ReNeuron Group Semi-Annual Data
Mar14 Sep14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -17.45 -43.05 -27.79 -94.49 -87.00

Competitive Comparison of ReNeuron Group's ROE % Adjusted to Book Value

For the Biotechnology subindustry, ReNeuron Group's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ReNeuron Group's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ReNeuron Group's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where ReNeuron Group's ROE % Adjusted to Book Value falls into.


;
;

ReNeuron Group ROE % Adjusted to Book Value Calculation

ReNeuron Group's ROE % Adjusted to Book Value for the fiscal year that ended in Mar. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-68.49% / 0.81
=-84.56%

ReNeuron Group's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-153.99% / 1.77
=-87.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ReNeuron Group ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of ReNeuron Group's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


ReNeuron Group Business Description

Traded in Other Exchanges
N/A
Address
Pencoed Business Park, Pencoed, Bridgend, GBR, CF35 5HY
ReNeuron Group PLC is engaged in the field of biotechnology. Its core activities include the research and clinical development of cell-based therapeutics. The company product pipeline includes the human retinal progenitor cell line (hRPC) and CTX neural cell line. It derives revenue from UK and U.S. The company is mainly focusing on the treatment of stroke disability, inherited retinal diseases, and cancer.

ReNeuron Group Headlines

From GuruFocus

ReNeuron Provides Program and Regulatory Approvals Update

By PRNewswire PRNewswire 06-17-2020

Half Year 2021 ReNeuron Group PLC Earnings Call Transcript

By GuruFocus Research 02-14-2024

ReNeuron Announces Clinical Update and Conference Presentations

By PRNewswire PRNewswire 10-02-2019

ReNeuron Expands Exosome IP Portfolio with Key Patent Grants

By PRNewswire PRNewswire 07-16-2019

Full Year 2022 ReNeuron Group PLC Earnings Call Transcript

By GuruFocus Research 02-14-2024

Edison Issues Update on ReNeuron Group (RENE)

By ACCESSWIRE ACCESSWIRE 06-23-2020

Edison Issues Update on ReNeuron Group (RENE)

By ACCESSWIRE ACCESSWIRE 07-06-2020

ReNeuron Update Regarding COVID-19

By PRNewswire PRNewswire 04-07-2020